The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease risk.
He developed extracorporeal membrane oxygenation, or ECMO, a treatment that can sustain patients whose hearts and lungs are failing — for days or weeks or longer.